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Based  on the  concerns  about  vaccine  hesitancy  and  its impact  on  vaccine  uptake  rates  and  the  per-
formance  of  national  immunization  programmes,  the  Strategic  Advisory  Group  of Experts  (SAGE) on
Immunization  Working  Group  on  Vaccine  Hesitancy  [1],  carried  out  a  review,  and  proposed  a  set of  rec-
ommendations  directed  to the  public  health  community,  to  WHO  and  its  partners,  and  to  the  World
Health  Organization  (WHO)  member  states.  The  ﬁnal  recommendations  issued  by SAGE  in October  2014
fall  into  three  categories:  (1)  those  focused  on  the  need  to increase  the  understanding  of  vaccine  hesi-ecommendations
accine acceptance
accine refusal
tancy,  its  determinants  and  the  rapidly  changing  challenges  it entails;  (2) those focused  on  dealing  with
the  structures  and  organizational  capacity  to  decrease  hesitancy  and  increase  acceptance  of  vaccines  at
the global,  national  and  local  levels;  (3)  and  those  focused  on  the sharing  of  lessons  learnt  and  effective
practices  from  various  countries  and settings  as well  as the  development,  validation  and  implementation
of  new  tools  to address  hesitancy.
© 2015  Published  by  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC  BY license  (http://
creativecommons.org/licenses/by/3.0/).. Introduction
The evidence demonstrating the beneﬁts of immunization is
verwhelming. Vaccination is one of the most successful and
ost-effective interventions known to improve health outcomes.
accines have saved countless lives and improved health and well-
eing around the world. However, vaccines can only improve health
nd prevent deaths if they are used. To prevent the morbidity
nd mortality associated with vaccine-preventable diseases at the
opulation level and to optimize control of vaccine-preventable
iseases in communities, immunization programmes must be able
o achieve and sustain high vaccine uptake rates.
High vaccination coverage is dependent on many factors. The
asic requirements are an understanding of the need and value of
accination in the population, and availability of vaccines as well
s accessible immunization services. One factor that has become
ncreasingly important to vaccination coverage is vaccine hesitancy
hat results in delay or refusal of vaccinations, ranging from delay
∗ Corresponding author.
E-mail address: juhani.eskola@thl.ﬁ (J. Eskola).
1 See SAGE Working Group on Vaccine Hesitancy members in Appendix.
ttp://dx.doi.org/10.1016/j.vaccine.2015.04.043
264-410X/© 2015 Published by Elsevier Ltd. This is an open access article under the CC Bin acceptance of one or more offered vaccines to complete refusal
of all vaccinations in the immunization programme.
As an example of vaccine hesitancy, during the A(H1N1) 2009
inﬂuenza pandemic, many countries in the Americas successfully
deployed inﬂuenza pandemic vaccine to the general public, but
many had difﬁculties in convincing pregnant women to accept
the vaccine [2]. Despite strong evidence of increased morbid-
ity and mortality caused by inﬂuenza, many pregnant women
hesitated to obtain pandemic inﬂuenza vaccination despite the rec-
ommendations provided by their health-care provider and their
country’s immunization programme leaders. Even improved access
to vaccination services did not reliably overcome this hesitation.
Reluctance to accept the measles vaccine in parts of Europe, the
human papillomavirus (HPV) vaccine in Japan and India, and the
polio vaccine in parts of Nigeria and Pakistan, are some other recent
examples of vaccine hesitancy from different parts of the world
[3–5].
Based on the concerns about this hesitancy and its impact on
vaccine uptake rates and the performance of national immuniza-
tion programmes, the SAGE Working Group on Vaccine Hesitancy
carried out a thorough review and proposed recommendations
on how to address vaccine hesitancy and its determinants [1].
The ﬁnal recommendations were issued by SAGE in October
2014, and include recommendations directed to the public health
Y license (http://creativecommons.org/licenses/by/3.0/).
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ommunity, to WHO  and its partners, and to the WHO  member
tates [6].
The ﬁnal recommendations issued by SAGE can be grouped into
hree categories. The ﬁrst category relates to the strong need to
ncrease understanding of vaccine hesitancy, its determinants and
he rapidly changing nature of the challenges that this hesitancy
ntails. The second focuses on the structures and organizational
apacity needed to decrease hesitancy and increase acceptance of
accines at global, national and local levels. The third relates to the
haring of lessons learnt and best practices based on experiences
rom various countries and settings as well as the development,
alidation, and implementation of new tools to address hesitancy.
astly, SAGE also proposed a list of research subject categories for
his rapidly emerging ﬁeld.
. Understanding of vaccine hesitancy should be increased
nd disseminated
Vaccine hesitancy refers to delay in acceptance or refusal of vac-
ines despite availability of vaccination services. It is a complex,
ontext-speciﬁc, and rapidly changing global problem that varies
cross time, place and vaccines [7].
Due to the complex nature of vaccine hesitancy, there is no sin-
le intervention strategy that can address all instances of vaccine
esitancy [8,9]. Dealing with vaccine hesitancy within a country
nd/or a population subgroup requires at ﬁrst an understanding of
he magnitude and setting of the problem and a diagnosis of its
oot causes. This is followed by the identiﬁcation and tailoring of
vidence-based strategies to address the root causes, and a sub-
equent evaluation to determine the impact of the interventions
nd monitoring whether vaccine acceptance has improved. Finally
n ongoing surveillance should be maintained to watch for possi-
le recurrence of the problem [10,11]. To help understanding the
ature and roots of the hesitancy, the Working Group developed
 matrix which describes the many determinants of vaccine hesi-
ancy [7]. This information should be widely disseminated to help
he public health community, organizations and countries to deal
ith the hesitancy challenge.
From a practical standpoint, it is important to understand that
accine hesitancy can be linked to several co-existing factors. For
nstance, when vaccine uptake is sub-optimal, concerns about vac-
ine safety may  be one discouraging factor in a setting where there
s also a problem of access to the available services; in such a sit-
ation the ﬁrst priority of the immunization programme would be
o improve access to vaccination services [7].
. Capacity to address hesitancy should be built up at
lobal, regional and country level
SAGE felt that WHO  should develop core capabilities at its head-
uarters and the regional level for gaining behavioural insights
hat could be applied to hesitancy [10,11]. This would require
he integrated skills and knowledge of sociologists, behavioural
sychologists, anthropologists, experts in social marketing and
ommunication as well as speciﬁc disease experts. Addressing the
ecessary behaviour change to overcome vaccine hesitancy is sim-
lar to the behaviour change needed to address other complex
ommunicable and noncommunicable disease problems such as
oor population compliance with the diagnosis and management
f chronic diseases such as hypertension, diabetes, and sexually
ransmitted infections. Cross-linkages between speciﬁc WHO  pro-
rammes should be strengthened as hesitancy is a cross-cutting
oncept which concerns various immunization-related ﬁelds.
WHO  should also engage partners, including civil society orga-
izations, at the global, regional and country levels, to mobilize (2015) 4215–4217
in support of immunization and to combat vaccine hesitancy. The
landscape of organizations active in the ﬁeld of vaccine hesitancy,
delineated by the Working Group, needs to be maintained and
updated as a resource to facilitate collaboration in global networks
of researchers and stakeholders working on vaccine hesitancy [12].
Given its vast experience in the ﬁeld of polio with exper-
tise in civil society organization, communications and behavioural
change, UNICEF is encouraged to continue the work with mem-
ber states and strengthen competencies in the ﬁeld of vaccine
hesitancy. Experiences from low income countries receive most
attention, but the lessons learnt that apply to vaccine hesitancy
more broadly need to be shared with high and middle income
countries. A notable example is the experience gained in a tackling
hesitancy in relation to polio vaccination [11,12].
Creation of an organizational structure, by both WHO  and
UNICEF, to address and coordinate vaccine hesitancy and demand
issues at their headquarters level, would facilitate a coordinated
cross-cutting approach to counteracting vaccine hesitancy glob-
ally, by building regional capacity to support countries in dealing
with vaccine hesitancy. Regional and country immunization advi-
sory committees should give consideration to vaccine hesitancy
issues and assist with dissemination of the products developed by
the Working Group [12].
WHO  member states are encouraged to incorporate a plan to
measure [13] and address vaccine hesitancy into their country’s
immunization programme as part of good programme practices.
Health-care workers should be educated and trained to deal with
vaccine hesitancy in patients and parents. Negative attitudes of
health-care workers towards vaccination strongly inﬂuence their
patients and potential vaccine recipients, and vaccine hesitant
behaviours among health-care workers need to be addressed. It
is also important to ensure education on vaccines and immu-
nization in general, and concerning vaccine-hesitant individuals
in particular, by inclusion of appropriate training in the curricula
of nursing, medical and other health-care students. The Working
Group also noted that ensuring education of younger individuals
about vaccines provides good opportunities to shape their beliefs
and behaviour in the future [11].
4. Sharing best practices and implementing new tools to
deal with vaccine hesitancy
Vaccine hesitancy is an emerging phenomenon, and many tools
to deal effectively with it are still in the development phase. Only
a few programmes and measures have been shown to be effec-
tive in decreasing vaccine hesitancy in speciﬁc populations where
hesitancy has been found [8–11]. Identifying the determinants in
the hesitant subgroup and then tailoring the intervention to ﬁt
the subgroup, setting and local resources is essential, as outcomes
are affected by many local factors related to the given contexts,
vaccines and populations. From acknowledging this basic princi-
ple, it becomes evident that regular updating and dissemination of
best practices and lessons learnt should be facilitated. This includes
regular synthesis, review and sharing of best practices for vaccine
hesitancy monitoring, intervention, and prevention, as well as pro-
moting training and making research ﬁndings available globally
and regionally.
SAGE encouraged the public health community to work together
to develop, validate and promote the use of tools to address
vaccine hesitancy, including tools for monitoring, diagnosis, inter-
vention, evaluation of impact, cost, and community acceptability.
This should be done in different settings and subpopulations in
high, middle, and low income countries, by creating or using oppor-
tunities for community input into vaccine hesitancy strategies to
ensure that they are acceptable to the local population [12].
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One potentially useful tool to address vaccine hesitancy is the
ailoring Immunization Programmes (TIP) model, developed by
HO/EURO [10], which should be validated in different popu-
ation groups and regions, and subsequently adapted to be used
lobally. Necessary support for training the trainers should be pro-
ided. Countries should be supported in using TIP, and sharing their
xperiences of its effectiveness with monitoring and evaluation of
utcomes, especially in low and middle income countries.
The review of intervention strategies [9] highlighted a num-
er of effective measures for improving vaccine uptake, including
easures to counteract hesitancy. Although more work is needed,
mmunization programmes should move ahead with incorporat-
ng the measures that ﬁt their setting and resources in order to
aintain or increase vaccination rates.
Integration of health prevention and intervention services with
ther health and non-health related initiatives has met  with consid-
rable success and needs to be applied more widely [6]. Vaccination
t both the individual and community levels should be included in
uch integrated services, which would help in overcoming hesi-
ancy due to complacency and convenience factors.
. Encourage and support research on vaccine hesitancy
As an emerging, complex, and evolving public health problem,
urther research is needed on vaccine hesitancy, including its preva-
ence, determinants, effective intervention strategies, prevention,
ecrudescence and early intervention, especially in low and middle
ncome countries, but also in high income countries. Furthermore,
esearch needs to be expanded to study factors at the individual
evel, but also at the community, contextual, and organizational
evels.
One of the main difﬁculties identiﬁed by the Working Group
as the lack of validated and standardized tools to assess and
easure vaccine hesitancy rates and underlying hesitancy deter-
inants across settings and between population groups, and for
onitoring trends over time [13]. A list of general hesitancy sur-
ey questions was developed by the Working Group but these
eed to be validated in different countries, as well as tested in
ifferent health-care systems, socio-cultural contexts, and vaccine
rogrammes, at the national, sub-national and local subgroup level.
owever, responses to these survey questions would need to be
nterpreted with caution.
Another difﬁculty identiﬁed was the lack of data on vaccine
esitancy levels in the populations where the interventions were
ested. Special attention needs to be paid to differences and sim-
larities between routine immunization programmes and mass
accination campaigns in different settings and contexts [6].
A third challenge identiﬁed concerns the evaluation of inter-
entions. Thus far most studies have not deﬁned vaccine hesitancy
n the study population and have only measured change in vac-
ine uptake, without assessing whether the intervention had any
mpact on hesitancy [9]. To avoid such a paucity of information,
oving forward whenever strategies to address vaccine hesitancy
re implemented, the population should be fully described, and
 rigorous evaluation should be conducted of the impact of the
ntervention and its components on vaccine hesitancy as well as
n vaccine acceptance.
It can be expected, as vaccine hesitancy evolves and new insights
nd information become available, that further research ques-
ions will continue to arise. The research portfolio therefore needs
o be expanded to encompass the multiple facets of this phe-
omenon at individual, community, and contextual levels in a
ulti-disciplinary effort to reduce vaccine hesitancy and ensure
hat satisfactory levels of vaccine uptake are achieved and sustained
n the future.
[ (2015) 4215–4217 4217
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